Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUREC trial of durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer
2024-515240-24-00Phase 2Authorised
- Sponsor
- GEMCAD
- Start
- Nov 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in rectal adenocarcinoma, sponsored by GEMCAD. Primary endpoint: Pathological complete response rate. Planned start Nov 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2024-515240-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515240-24-00.